COLLABORATIONS
EMPOWERING THE FUTURE OF PET
With 50 years of passion and dedication, we have taken bold steps to advance the development of next generation theranostic agents through both research and commercial scientific collaborations.
GE HealthCare
GE HealthCare and SOFIE Biosciences (SOFIE) announced a partnership to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP).
Lantheus Holdings
SOFIE signed a commercial supply agreement with Lantheus Holdings, Inc. (the parent company of Progenics Pharmaceuticals, Inc. (Progenics)) to manufacture and distribute Lantheus’ lead investigational prostate cancer imaging agent, PyL™ (18F-DCFPYL).
Life Molecular Imaging
Life Molecular Imaging (LMI) develops novel PET tracers for molecular imaging. LMI’s product, Neuraceq™, is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. SOFIE is an authorized user for preparation, distribution, and redistribution of Neuraceq™.
Curium Pharma
Curium is a leading provider of radiopharmaceuticals for their use in nuclear medicine. One of Curium’s products is Detectnet™ (copper Cu 64 dotatate; RadioMedix and Curium), a radioactive diagnostic agent, for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NET) in adult patients. SOFIE is an authorized user for preparation, distribution, and redistribution of Detectnet™.